Thomson PharmaSM - Integration enhances communication
Thomson Scientific, part of the Thomson Corporation, is a global leader in providing integrated information solutions to professionals working at all stages of the drug lifecycle. For decades, we have provided authoritative content to the Pharmaceutical and Biotechnology markets. With the launch of Thomson PharmaSM, which integrates this content into a customizable workflow solution, we are re-engineering the drug development process.
Current trends indicate that key departments and teams within organizations have overlapping data requirements, but need to process that data in a variety of different ways. This data is much easier to access and share if it's available through one integrated solution.
Thomson Pharma integrates the best of the drug, intellectual property, literature and news, company, target, chemistry, and sequencing content owned by Thomson in a single solution. It enables professionals working at all stages of the drug development pipeline, from clinical researchers and chemists to competitive intelligence and licensing and business development professionals, to annotate and share a common source of integrated information.
By combining powerful annotation and file sharing features with premium content, Thomson Pharma encourages collaboration, enhances communication, and expedites decision-making across departments and enhances an organization's ability to innovate, work faster and smarter, and attain outstanding research and business results.
Thomson Pharma
can help your organization to:
To find out more, visit: www.thomsonpharma.com
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.